Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.

Cancer Research UK Manchester Institute The University of Manchester Manchester United Kingdom

Department of Dermatology Instituto Valenciano de Oncologia Valencia Spain

Division of Functional Genome Analysis German Cancer Research Center Heidelberg Germany; Institute of Medical Biometry and Informatics University of Heidelberg Heidelberg Germany; Department of Molecular Biology of Cancer Institute of Experimental Medicine CAS Czech Academy of Sciences Prague Czech Republic

J Invest Dermatol. 2022 Feb;142(2):435-444. doi: 10.1016/j.jid.2021.07.160. PubMed

References provided by Crossref.org